Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as Add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms J-RAPID
- Sponsors Otsuka Pharmaceutical
- 06 Jun 2020 Results pooled analysis of efficacy from 4 trials (RAPID 1, RAPID 2, J-RAPID and RAPID-C), presented at the 21st Annual Congress of the European League Against Rheumatism
- 04 Jun 2020 According to an UCB media release, post-hoc analysis results from the pooled studies RAPID 1 (NCT00152386), RAPID 2 (NCT00175877), J-RAPID (NCT00791999) and RAPID-C (NCT02151851) were presented at the Annual European Congress of Rheumatology (EULAR) 2020.
- 23 Apr 2015 According to an Astellas Pharma media release, 4-year data from this study were presented at the Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology 2015.